Hangzhou Biotest Biotech Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hangzhou Biotest Biotech Co., Ltd.

Why is Hangzhou Biotest Biotech Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -39.27% and Operating profit at -61.76% over the last 5 years

With a fall in Net Sales of -11.75%, the company declared Very Negative results in Mar 25

DEBT-EQUITY RATIO (HY) Highest at -67.14 %
NET SALES(Q) Lowest at CNY 84.55 MM
OPERATING PROFIT(Q) Lowest at CNY -1.05 MM

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Hangzhou Biotest Biotech Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Hangzhou Biotest Biotech Co., Ltd.

61.23%

1.66

59.80%

China Shanghai Composite

15.44%

1.06

14.51%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-39.27%

EBIT Growth (5y)

-61.76%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.67

Sales to Capital Employed (avg)

0.22

Tax Ratio

15.45%

Dividend Payout Ratio

92.48%

Pledged Shares

Institutional Holding

ROCE (avg)

119.24%

ROE (avg)

13.43%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.59

EV to EBIT

74.24

EV to EBITDA

55.25

EV to Capital Employed

5.61

EV to Sales

9.23

PEG Ratio

Dividend Yield

ROCE (Latest)

7.56%

ROE (Latest)

4.60%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

At CNY 89.03 MM has Grown at 62.93%

RAW MATERIAL COST(Y)

Fallen by -5.75% (YoY

-17What is not working for the Company

DEBT-EQUITY RATIO (HY)

Highest at -67.14 %

NET SALES(Q)

Lowest at CNY 84.55 MM

OPERATING PROFIT(Q)

Lowest at CNY -1.05 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -1.24 %

PRE-TAX PROFIT(Q)

Lowest at CNY 10.42 MM

NET PROFIT(Q)

Lowest at CNY 8.94 MM

EPS(Q)

Lowest at CNY 0.06

Here's what is working for Hangzhou Biotest Biotech Co., Ltd.

Raw Material Cost

Fallen by -5.75% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hangzhou Biotest Biotech Co., Ltd.

Net Sales

At CNY 84.55 MM has Fallen at -37.03%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Pre-Tax Profit

At CNY 10.42 MM has Fallen at -76.76%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 8.94 MM has Fallen at -77.43%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Debt-Equity Ratio

Highest at -67.14 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Net Sales

Lowest at CNY 84.55 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY -1.05 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at -1.24 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CNY 10.42 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

Lowest at CNY 8.94 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS

Lowest at CNY 0.06

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Non Operating Income

Highest at CNY 1.13 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income